Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic phase II first-line mantle cell lymphoma transplant study with Zevalin intensification
2005-002003-17Phase 2Completed
- Sponsor
- Rikshospitalet-Radiumhospitalet
- Start
- May 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL) (2 arms), sponsored by Rikshospitalet-Radiumhospitalet. Primary endpoints: Time to treatment failure and Safety. Started May 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2005-002003-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002003-17.